1. Home
  2. CANF vs MATH Comparison

CANF vs MATH Comparison

Compare CANF & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.40

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$1.15

Market Cap

53.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
MATH
Founded
1994
2015
Country
Israel
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
53.8M
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
CANF
MATH
Price
$3.40
$1.15
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9,750.00
N/A
AVG Volume (30 Days)
609.7K
41.5K
Earning Date
03-27-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$461.72
N/A
Revenue Next Year
$290,391.28
N/A
P/E Ratio
N/A
$3.10
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$1.10
52 Week High
$10.40
$4.17

Technical Indicators

Market Signals
Indicator
CANF
MATH
Relative Strength Index (RSI) 37.47 34.84
Support Level $0.60 $1.10
Resistance Level $4.74 $3.16
Average True Range (ATR) 0.65 0.07
MACD -0.18 0.03
Stochastic Oscillator 0.57 12.05

Price Performance

Historical Comparison
CANF
MATH

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

Share on Social Networks: